Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Male germ cell tumors.

T H Guthrie, H A Hatfield

    American Family Physician
    |October 1, 1983
    PubMed
    Summary

    New male germ cell tumor treatments significantly improve survival and cure rates. Therapy is now individualized based on cancer specifics, achieving high success for both seminomas and nonseminomatous types.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

    Leukemia·2017
    Same author

    Ureteral obstruction secondary to seminoma of testis.

    Medical record and annals·2010
    Same author

    Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption.

    American journal of hematology·1997
    Same author

    Carcinoembryonic antigen: the old dog finally learns new tricks.

    Digestive diseases (Basel, Switzerland)·1996
    Same author

    A pilot study of iontophoretic cisplatin chemotherapy of basal and squamous cell carcinomas of the skin.

    Archives of dermatology·1993
    Same author

    Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma.

    Cancer·1993

    Area of Science:

    • Oncology
    • Urology

    Background:

    • Male germ cell tumors (GCTs) are a significant concern in urologic oncology.
    • Historically, treatment involved broad approaches like surgery and radiation therapy for all GCTs.

    Purpose of the Study:

    • To highlight advancements in male GCT treatment.
    • To emphasize the shift towards personalized therapeutic strategies.

    Main Methods:

    • Review of contemporary treatment paradigms for male germ cell tumors.
    • Focus on individualized therapy selection based on key prognostic factors.

    Main Results:

    • Modern treatment approaches have dramatically improved survival and cure rates for male GCTs.
    • Cure rates now reach 95% for seminomas.
    • Cure rates reach 80% for nonseminomatous germ cell tumors.

    Conclusions:

    • Individualized therapy, guided by histology, stage, and serum tumor markers, is the current standard for male GCTs.
    • These tailored strategies have led to unprecedented success in treating these neoplasms.